MA44503B1 - Composés de pyrrolotriazine en tant qu'inhibiteurs de tam - Google Patents

Composés de pyrrolotriazine en tant qu'inhibiteurs de tam

Info

Publication number
MA44503B1
MA44503B1 MA44503A MA44503A MA44503B1 MA 44503 B1 MA44503 B1 MA 44503B1 MA 44503 A MA44503 A MA 44503A MA 44503 A MA44503 A MA 44503A MA 44503 B1 MA44503 B1 MA 44503B1
Authority
MA
Morocco
Prior art keywords
pyrrolotriazine compounds
inhibitors
tam inhibitors
compounds
tam
Prior art date
Application number
MA44503A
Other languages
English (en)
Other versions
MA44503A (fr
Inventor
xiaozhao Wang
Chunhong He
Yun-Long Li
Joseph Barbosa
David M Burns
Hao Feng
Joseph Glenn
Taisheng Huang
Song Mei
Jincong Zhuo
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Priority claimed from PCT/US2017/024270 external-priority patent/WO2017172596A1/fr
Publication of MA44503A publication Critical patent/MA44503A/fr
Publication of MA44503B1 publication Critical patent/MA44503B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette demande concerne des composés de formule i, ou des sels pharmaceutiquement acceptables de ceux-ci, qui sont des inhibiteurs de tam kinases utiles pour le traitement de troubles tels que le cancer.
MA44503A 2016-03-28 2017-03-27 Composés de pyrrolotriazine en tant qu'inhibiteurs de tam MA44503B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314066P 2016-03-28 2016-03-28
PCT/US2017/024270 WO2017172596A1 (fr) 2016-03-28 2017-03-27 Composés de pyrrolotriazine en tant qu'inhibiteurs de tam

Publications (2)

Publication Number Publication Date
MA44503A MA44503A (fr) 2019-02-06
MA44503B1 true MA44503B1 (fr) 2023-11-30

Family

ID=63036861

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44503A MA44503B1 (fr) 2016-03-28 2017-03-27 Composés de pyrrolotriazine en tant qu'inhibiteurs de tam

Country Status (2)

Country Link
AR (1) AR107984A1 (fr)
MA (1) MA44503B1 (fr)

Also Published As

Publication number Publication date
AR107984A1 (es) 2018-07-04
MA44503A (fr) 2019-02-06

Similar Documents

Publication Publication Date Title
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA54386B1 (fr) Modulateurs de trex1
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA38483A1 (fr) Inhibiteurs de l'ido
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA54133B1 (fr) Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
TN2015000347A1 (fr) Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA50398B1 (fr) Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA46965B1 (fr) Modulateurs de gamma ror (rory)